TY - JOUR T1 - First study on mental distress in Brazil during the COVID-19 crisis JF - medRxiv DO - 10.1101/2020.04.18.20070896 SP - 2020.04.18.20070896 AU - Stephen X. Zhang AU - Yifei Wang AU - Asghar Afshar Jahanshahi AU - Jianfeng Jia AU - Valentina Gomes Haensel Schmitt Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/23/2020.04.18.20070896.abstract N2 - Objective We aim to provide the first evidence of mental distress and its associated predictors among adults in the ongoing COVID-19 crisis in Brazil.Methods We conducted a primary survey of 638 adults in Brazil on March 25–28, 2020, about one month (32 days) after the first COVID-19 case in South America was confirmed in São Paulo.Results In Brazil, 52% (332) of the sampled adults experienced mild or moderate distress, and 18.8% (120) suffered severe distress. Adults who were female, younger, more educated, and exercised less reported higher levels of distress. Each individual’s distance from the Brazilian epicenter of São Paulo interacted with age and workplace attendance to predict the level of distress. The “typhoon eye effect” was stronger for people who were older or attended their workplace less. The most vulnerable adults were those who were far from the epicenter and did not go to their workplace in the week before the survey.Conclusion Identifying the predictors of distress enables mental health services to better target finding and helping the more mentally vulnerable adults during the ongoing COVID-19 crisis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN.A.Funding StatementN.A.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable after publications in a journal ER -